fampridine

Phase 3Small molecule

Biogen

fampridine is one of 137 small molecule programs targeting Cerebellar Ataxia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

136

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebellar AtaxiaActive, not recruiting

CognitionActive, not recruiting

Gastrointestinal Stromal TumorActive, not recruiting

Multiple SclerosisActive, not recruiting

Cerebellar AtaxiaPhase 3

Active, not recruiting

CognitionPreclinical

Active, not recruiting

Gastrointestinal Stromal TumorPhase 1

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

fampridine

Biogen

Phase 3

5 2

Betaseron

Bayer

Preclinical

16 3

Kesimpta

Novartis

Preclinical

15 4

Tysabri

Biogen

Preclinical

14 5

Avonex

EMD Serono

Preclinical

22 6

Campath

GGenzyme, a Sanofi Company

Preclinical

12 7

Flomax

Sanofi

Preclinical

1 8

Pred Forte

Myfortic

Novantrone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Cerebellar Ataxia

NCT07185347

Q3 2031

Phase 1Recruiting

Gastrointestinal Stromal Tumor

NCT07171203

Clinical

Trials by Indication[1]

Multiple Sclerosis5 trials

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

Completed· Biogen logo

Biogen·Phase 3·NCT02219932·646 enrolled

Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.

Completed·—·Phase 4·NCT02849782·89 enrolled

Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis

Unknown status·UUniversity of Zurich·Phase 2·NCT01576354·70 enrolled

Show 2 more trials

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

Completed· Biogen logo

Biogen·Phase 4·NCT01480076·901 enrolled

Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique

Completed·UUniversity of Southern Denmark·N/A·NCT03847545·48 enrolled

Effectiveness1 trial

A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS

Completed·UUniversity College Dublin·Phase 4·NCT02208050·64 enrolled

Cerebellar Ataxia1 trial

A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07185347·70 enrolled

Prolonged1 trial

Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients

Completed·CClinique Neuro-Outaouais·Phase 4·NCT02146534·44 enrolled

Observational Study1 trial

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice

Completed· Biogen logo

Biogen··NCT01480063·4,734 enrolled

3 more indications

Pregnancy1 trial

Fampridine Pregnancy Exposure Registry

Terminated· Biogen logo

Biogen··NCT01532154·1 enrolled

Cognition1 trial

Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis

Completed·GGenesis Pharma CNS & Specialty··NCT03164018·111 enrolled

Gastrointestinal Stromal Tumor1 trial

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

Recruiting·UUniversity of California, San Diego·Phase 1·NCT07171203·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for fampridine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fampridine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fampridine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Biogen

fampridine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2031

Trials by Indication[1]

Multiple Sclerosis5 trials

Effectiveness1 trial

Cerebellar Ataxia1 trial

Prolonged1 trial

Observational Study1 trial

Pregnancy1 trial

Cognition1 trial

Gastrointestinal Stromal Tumor1 trial

References

Drug Info

Quick Facts

Related News